Quality of management of oral anticoagulation as assessed by time in therapeutic INR range in elderly and younger patients with low mean years of formal education: A prospective cohort study

Age and Ageing

Volumn 40, Issue 3, 2011, Pages 375-381

  de Barros Costa, Gustavo Lamego ^a   Ferreira, Diana Carvalho ^a   Valacio, Reginaldo Aparecido ^a   da Consolaçao Vieira Moreira, Maria ^b  

^a Hospital Municipal Odilon Behrens   (Brazil)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Elderly; Oral anticoagulation; Quality of health care; Time in therapeutic range; Warfarin

Indexed keywords

ANTICOAGULANT AGENT;

ADULT; AGED; ANTICOAGULATION; ARTICLE; BLOOD CLOTTING TIME; COGNITIVE DEFECT; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DEVELOPING COUNTRY; DIABETES MELLITUS; EDUCATIONAL STATUS; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEALTH CARE QUALITY; HEART ATRIUM FIBRILLATION; HEART FAILURE; HUMAN; INTERNATIONAL NORMALIZED RATIO; KIDNEY FAILURE; LONG TERM CARE; MALE; NONVALVULAR ATRIAL FIBRILLATION; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; POLYPHARMACY; PRIORITY JOURNAL; PROSPECTIVE STUDY; TIME IN THERAPEUTIC INTERNATIONAL NORMALIZED RATIO RANGE; VALVULAR HEART DISEASE; VENOUS THROMBOEMBOLISM;

ADMINISTRATION, ORAL; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; BRAZIL; CARDIOVASCULAR DISEASES; EDUCATIONAL STATUS; FEMALE; FOLLOW-UP STUDIES; HOSPITALS, PUBLIC; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PROSPECTIVE STUDIES; QUALITY OF HEALTH CARE; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79955453634     PISSN: 00020729     EISSN: 14682834     Source Type: Journal    
DOI: 10.1093/ageing/afr020     Document Type: Article

References (37)

1. Ansell J, Hirsh J, Hylek E et al. Pharmacology and Management of the Vitamin K Antagonists. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 160S-98S.
2. Gallagher AM, Rietbrock S, Plumb J et al. Initiation and persistence of warfarin or aspirin in patients with chronic atrial fibrillation in general practice: do the appropriate patients receive stroke prophylaxis? J Thromb Haemost 2008; 6: 1500-6.
3. Go AS, Hylek EM, Borowsky LH et al. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: The AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. Ann Intern Med 1999; 131: 927-34.
4. Ogilvie IM, Newton N, Welner SA et al. Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med 2010; 123: 638-45.
5. Evans A, Kalra L.. Are the results of randomized controlled trials on anticoagulation in patients with atrial fibrillation generalizable to clinical practice? Arch Intern Med 2001; 161: 1443-7.
6. Wittkowsky AK. Effective anticoagulation therapy: defining the gap between clinical studies and clinical practice. Am J Manag Care 2004; 10: S297-306.
7. Kaatz S. Determinants and measures of quality in oral anticoagulation therapy. J Thromb Thrombolysis 2008; 25: 61-66.
8. Rose AJ, Berlowitz DR, Frayne SM et al. Measuring quality of oral anticoagulation care: extending quality measurement to a new field. Jt Comm J Qual Patient Saf 2009; 35: 146-55.
9. Lackie CL, Garbarino KA, Pruetz JA. Warfarin therapy for atrial fibrillation in the elderly. Ann Pharmacother 2002; 36: 200-4.
10. Taggar JS, Lip GYH. Anticoagulation for elderly patients with atrial fibrillation: not to be neglected. Europace 2008; 10: 1-2.
11. Abdelhafiz AH, Wheeldon NM. Risk factors for bleeding during anticoagulation of atrial fibrillation in older and younger patients in clinical practice. Am J Geriatr Pharmacother 2008; 6: 1-11.
12. Du X, Ma CS, Liu XH et al. Anticoagulation control in atrial fibrillation patients present to outpatient clinic of cardiology versus anticoagulant clinics. Chin Med J (Engl) 2005; 118: 1206-9.
13. Rose AJ, Hylek EM, Ozonoff A et al. Patient characteristics associated with oral anticoagulation control: results of the Veterans AffaiRs Study to Improve Anticoagulation (VARIA). J Thromb Haemost 2010; 8: 2182-91.
14. Staab JP, Datto CJ, Weinrieb RM et al. Detection and diagnosis of psychiatric disorders in primary medical care settings. Med Clin North Am 2001; 85: 579-96.
15. Almeida OP. Mini exame do estado mental e o diagnóstico de demência no Brasil. Arq Neuropsiquiatr 1998; 56(3-B): 605-12.
16. Morisky DE, Green LW, Levine DM. Concurrent and predective validity of self-reported measure of medication adherence. Med Care 1986; 24: 67-74.
17. Edelberg HK, Shallenberger E, Wei JY. Medication management capacity in highly functioning community-living older adults: detection of early deficits. J Am Geriatr Soc 1999; 47: 592-6.
18. Rosendaal FR, Cannegieter SC, van der Meer FJM et al. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993; 69: 236-9.
19. Steinman MA, Seth Landefeld C, Rosenthal GE et al. Polypharmacy and prescribing quality in older people. J Am Geriatr Soc 2006; 54: 1516-23.
20. Ingelgard A, Hollowell J, Reddy P et al. What are the barriers to warfarin use in atrial fibrillation? Development of a questionnaire. J Thromb Thrombolysis 2006; 21: 257-65.
21. Vasishta S, Toor F, Johansen A et al. Stroke prevention in atrial fibrillation: physicians' attitudes to anticoagulation in older people. Arch Gerontol Geriatr 2001; 33: 219-26.
22. White RH, Gruber M, Feyzi J et al. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control. Results From SPORTIF III and V. Arch Intern Med 2007; 167: 239-45.
23. Rose AJ, Ozonoff A, Henault LE et al. Warfarin for atrial fibrillation in community-based practise. J Thromb Haemost 2008; 6: 1647-54.
24. Fang MC, Chang Y, Hylek EM et al. Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. Ann Intern Med 2004; 141: 745-52.
25. Torn M, Bollen WL, van der Meer FJ et al. Risks of oral anticoagulant therapy with increasing age. Arch Intern Med 2005; 165: 1527-32.
26. Man-Son-Hing M, Laupacis A. Anticoagulant-related bleeding in older persons with atrial fibrillation. Physicians' fears often unfounded. Arch Intern Med 2003; 163: 1580-6.
27. Jacobs LG. Warfarin pharmacology, clinical management, and evaluation of hemorrhagic risk for the elderly. Clin Geriatr Med 2006; 22: 17-32.
28. McCormick D, Gurwitz JH, Goldberg J et al. Long-term anticoagulation therapy for atrial fibrillation in elderly patients: efficacy, risk, and current patterns of use. J Thromb Thrombolysis 1999; 7: 157-63.
29. Cheng H. Is age a risk factor for warfarin-related major bleeds in elderly patients with atrial fibrillation? J Am Geriatr Soc 2006; 54: 1155.
30. Zehnder BS, Schaer BA, Jeker U et al. Atrial fibrillation: estimated increased rate of stroke due to lacking adherence to guidelines. Swiss Med Wkly 2006; 136: 757-60.
31. Odén A, Fahlén M. Oral anticoagulation and risk of death: a medical record linkage study. BMJ 2002; 325: 1073-5.
32. Veeger NJGM, Piersma-Wichers M, Tijssen JG et al. Individual time within target range in patients treated with vitamin K antagonists: main determinant of quality of anticoagulation and predictor of clinical outcome. A retrospective study of 2300 consecutive patients with venous thromboembolism. Br J Haematol 2005; 128: 513-9.
33. Jones M, McEwan P, Morgan CL et al. Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with nonvalvar atrial fibrillation: a record linkage study in a large British population. Heart 2005; 91: 472-7.
34. van Walraven C, Oake N, Wells PS et al. Burden of potentially avoidable anticoagulant-associated hemorrhagic and thromobembolic events in the elderly. Chest 2007; 131: 1508-15.
35. Connolly SJ, Pogue J, Eikelboom J et al. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation 2008; 118: 2029-37.
36. van Leeuwen Y, Rosendaal FR, Cannegieter SC. Prediction of hemorrhagic and thrombotic events in patients with mechanical heart valve prostheses treated with oral anticoagulants. J Thromb Haemost 2008; 6: 451-6.
37. van Walraven C, Jennings A, Oake N et al. Effect of study setting on anticoagulation control: a systematic review and metaregression. Chest 2006; 129: 1155-66.